SCHEMBL6418503

SCHEMBL6418503

CN1C(=O)CCN(c2ccccc2)C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
KMT2A Q03164 1/20 0.59
DDB1 Q16531 1/20 0.49
CRBN Q96SW2 1/20 0.49
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44
HSD11B1 P28845 1/20 0.41
POLB P06746 2/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
CTSG P08311 1/20 0.40
CMA1 P23946 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10973333 0.85 DDB1 (0.51) MEN1NPC1RAB9AKMT2ADDB1
Hydrochloric Acid SCHEMBL9819431 0.84 DDB1 (0.50) MEN1NPC1RAB9AKMT2ADDB1
SCHEMBL9819344 0.84 DRD2 (0.48) MEN1KMT2ADRD2DRD3HSD11B1
SCHEMBL2536250 0.82 NPC1 (0.54) MEN1NPC1RAB9AKMT2APOLB
SCHEMBL4420931 0.82 DDB1 (0.46) MEN1NPC1RAB9AKMT2ADDB1
SCHEMBL20095543 0.82 SIGMAR1 (0.55) MEN1NPC1RAB9AKMT2ADDB1
SCHEMBL25575682 0.82 L3MBTL1 (0.54) DRD2DRD3HSD11B1ALDH1A1MAPT
SCHEMBL9819448 0.82 DRD2 (0.52) MEN1KMT2ADRD2DRD3ALDH1A1
SCHEMBL25667202 0.81 DRD2 (0.49) MEN1NPC1RAB9AKMT2ADRD2
SCHEMBL136822 0.80 NPC1 (0.60) MEN1NPC1RAB9AKMT2ADDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-09-21 US disclosed
EP-1317013-B1 NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME MITSUBISHI CHEM CORP (JP) 2017-03-15 EP disclosed
US-6942948-B2 Nonaqueous electrolyte solution and secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2005-09-13 US disclosed
US-20030165733-A1 Nonaqueous electrolyte solution and secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2003-09-04 US disclosed
EP-1317013-A1 NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2003-06-04 EP disclosed
EP-0162669-B1 ANTICONVULSIVE COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-12-11 EP disclosed
US-4588729-A Treating convulsions with dihydrouracil derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1986-05-13 US disclosed
EP-0162669-A2 Anticonvulsive compounds KYOWA HAKKO KOGYO CO., LTD. (JP) 1985-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS RAB1A, SOS1, IQGAP1 MEN1 236/4885NPC1 19/4885RAB9A 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.